A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity
PLOS One · 2025
DOI: 10.1371/journal.pone.0321169 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Keifer G Kurtz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology Program, Sloan Kettering Institute, New York, United States of America. Hauptthemen laut MEDLINE: Receptors, Immunologic, Macrophages, Antibodies, Monoclonal, Antigens, Differentiation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Greenberg Medical Research Institute.
Abstract (Originalsprache)
Several T cell immune checkpoint blockade therapies have shown initial successes in multiple cancers. However, significant issues remain, including tumor relapse, severe toxicities, and a lack of efficacy in most patients. SIRPα, commonly known as the “do not eat me signal”, is a monocyte checkpoint cell surface protein. Agents that block the interaction of CD47 with SIRPα have recently shown clinical success in combination with monoclonal antibody therapy to potentiate macrophage phagocytosis of tumors. However, significant toxicities and logistical issues are associated with CD47-targeted agents due to the expression of CD47 on all human cells. In contrast, SIRPα has expression limited to myelomonocytic cells, meaning highly specific SIRPα blocking agents might reduce these toxicities and avoid the target antigen sink. Herein, we generated a high affinity and highly specific SIRPα-targeting monoclonal antibody, F05, that has enhanced SIRPα binding and reduced SIRPβ and SIRPγ binding capacity when compared to other available SIRPα antibodies. Furthermore, we show F05 reprograms immunosuppressive macrophages toward a phagocytic profile in vitro . F05 demonstrated efficacy in solid tumor animal models, providing a rationale for further development of the antibody.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Molecular Pharmacology Program, Sloan Kettering Institute, New York, United States of America.
- Pharmacology Program, Weill Cornell Medicine, New York, United States of America.
- Tri-Institutional Therapeutics Discovery Institute, Weill Cornell Medicine, New York, United States of America.
- Tri-Institutional MD-PhD Program, Weill Cornell Medicine, New York, United States of America.
- Department of Medicine, Memorial Hospital, New York, United States of America.
ORCID-Profile: Keifer G Kurtz, Olivia Vergnolle, David A Scheinberg
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Greenberg Medical Research Institute
- Emerson Collective
Zitieren
APA
Kurtz, K. G., Lebedeva, I., Pierre, S. A., Andrew, D., Liao, Y. R., Ambriz, D., Vergnolle, O., Shen, L., Nyakatura, E., Baca, M., & Scheinberg, D. A. (2025). A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity. PLOS One. https://doi.org/10.1371/journal.pone.0321169
Vancouver
Kurtz KG, Lebedeva I, Pierre SA, Andrew D, Liao YR, Ambriz D, et al. A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity. PLOS One. 2025. doi:10.1371/journal.pone.0321169
BibTeX
@article{Kurtz2025,
author = {Kurtz, Keifer G and Lebedeva, Irina and Pierre, Stephanie A and Andrew, David and Liao, Yu-Rou and Ambriz, Daisy and Vergnolle, Olivia and Shen, Leyi and Nyakatura, Elizabeth and Baca, Manuel and Scheinberg, David A},
title = {A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0321169}
}
EUVIMED